Selected article for: "Arbidol group and control group"
Author: Yueping Li; Zhiwei Xie; Weiyin Lin; Weiping Cai; Chunyan Wen; Yujuan Guan; Xiaoneng Mo; Jian Wang; Yaping Wang; Ping Peng; Xudan Chen; Wenxin Hong; Guangming Xiao; Jinxin Liu; Lieguang Zhang; Fengyu Hu; Feng Li; Feng Li; Fuchun Zhang; Xilong Deng; Linghua Li
Title: An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)
  • Document date: 2020_3_23
    • ID: 9hknw4ws_47
    Snippet: During the study period, a total of 13 (15.1%) patients progressed to severe/critical clinical status including 8 receiving LPV/r, 3 receiving arbidol and 2 in the control group, which indicates that disease condition could still worsen even after hospitalization, and thus urgently demands rigorous observation of illness and care. Fortunately, by the endpoint of this study twelve patients had been discharged from hospital after recovery, and only.....
    Document: During the study period, a total of 13 (15.1%) patients progressed to severe/critical clinical status including 8 receiving LPV/r, 3 receiving arbidol and 2 in the control group, which indicates that disease condition could still worsen even after hospitalization, and thus urgently demands rigorous observation of illness and care. Fortunately, by the endpoint of this study twelve patients had been discharged from hospital after recovery, and only one patient remained hospitalized, albeit with significant clinical improvement. This gives us confidence that even in the absence of specific antiviral drugs, the vast majority of COVID-19 patients in severe/critical clinical status can still recover after comprehensive treatment.

    Search related documents:
    Co phrase search for related documents
    • critical clinical status and severe critical clinical status: 1, 2, 3
    • critical clinical status and study period: 1
    • disease condition and hospital discharge: 1, 2, 3, 4, 5
    • disease condition and specific antiviral drug: 1
    • disease condition and study period: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • hospital discharge and patient recovery hospital discharge: 1, 2, 3
    • hospital discharge and recovery hospital discharge: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61
    • hospital discharge and significant clinical improvement: 1, 2, 3, 4, 5, 6, 7, 8
    • hospital discharge and study endpoint: 1, 2, 3, 4, 5
    • hospital discharge and study period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
    • hospital discharge and vast majority: 1, 2, 3, 4, 5, 6, 7
    • patient recovery hospital discharge and recovery hospital discharge: 1, 2, 3
    • receive arbidol and severe critical clinical status: 1, 2
    • recovery hospital discharge and significant clinical improvement: 1
    • recovery hospital discharge and study period: 1, 2
    • significant clinical improvement and specific antiviral drug: 1
    • significant clinical improvement and study endpoint: 1
    • significant clinical improvement and study period: 1, 2, 3
    • study period and vast majority: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14